New hope for lung cancer: YL201 takes on relapsed SCLC in major trial
NCT ID NCT06612151
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 study compares a new drug called YL201 to the standard treatment topotecan in 438 adults with relapsed small cell lung cancer. The goal is to see if YL201 helps people live longer. Participants receive either YL201 by infusion every three weeks or topotecan by injection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- YL201
- What this could lead to
- If YL201 works better than topotecan, it could offer a new treatment option for people with relapsed small cell lung cancer, potentially extending survival.
- What could go wrong
- This is still an experimental drug in a Phase 3 trial. It may not prove superior to the existing treatment, and side effects are unknown at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells boost lung cancer remission?
- Could adding chest radiation extend life in advanced lung cancer?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Can a new drug tame advanced solid tumors?
- Can a remote approach bring clinical trials to lung cancer patients?
- Which palliative care approach boosts quality of life in advanced lung cancer?